Last reviewed · How we verify
NeuroAiD
NeuroAiD is a traditional Chinese medicine-derived neuroprotective agent that promotes neuronal survival and enhances neuroplasticity following acute ischemic stroke.
NeuroAiD (MLC901) is a small molecule drug developed by CHIMES Society, primarily for neurological conditions. It has completed several Phase 3 and 4 trials, showing promise in traumatic brain injury and stroke recovery. Despite no FDA approval, it is being studied for Alzheimer's disease and spinal cord injury.
At a glance
| Generic name | NeuroAiD |
|---|---|
| Also known as | MLC601, MLC901, Danqi Piantan Jiaonang (In China) |
| Sponsor | CHIMES Society |
| Drug class | Herbal neuroprotective agent |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
NeuroAiD contains multiple herbal components that work through multiple pathways including anti-inflammatory, antioxidant, and neurotrophic mechanisms. It is believed to enhance neuronal repair and functional recovery by promoting synaptic plasticity and reducing secondary neuronal damage in the post-stroke period.
Approved indications
- Acute ischemic stroke (within 72 hours of onset)
- Post-stroke neurological recovery and rehabilitation
Common side effects
- Gastrointestinal disturbances
- Headache
- Dizziness
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NeuroAiD CI brief — competitive landscape report
- NeuroAiD updates RSS · CI watch RSS
- CHIMES Society portfolio CI